secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001193125-23-190147
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Bio Phase 2 flu prevention trial misses endpoints; cash ~$1.9B
------------------------------------------------------------------

- Phase 2 PENINSULA trial of VIR-2482 did not meet primary or secondary efficacy endpoints for preventing symptomatic influenza A.
- Highest dose (1,200 mg) showed non-statistically significant 16% reduction in protocol-defined influenza A illness vs placebo.
- Secondary endpoint (CDC-defined ILI) showed 57% reduction, but not statistically significant (95% CI -2.51 to 82.15).
- VIR-2482 was generally well tolerated; no safety signals identified; ~3,000 participants enrolled.
- Cash, cash equivalents and investments were approximately $1.9 billion as of June 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523190147/0001193125-23-190147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523190147/d517183d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-190147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer